Non-Small Cell Lung Cancer Recurrent and Metastatic Disease

On this page

Quick Reference

RxDrug of choiceOsimertinib 80 mg daily for EGFR-mutant NSCLC; pembrolizumab 200 mg IV every 3 weeks for PD-L1 ≥50% without driver alterations

AltAlternativesAumolertinib 110 mg daily + platinum-pemetrexed for EGFR-mutant; sunvozertinib 300 mg daily for EGFR exon20ins; poziotinib 16 mg daily for HER2 exon20ins; lazertinib 240 mg daily + SBRT for oligometastatic EGFR-mutant

⊘AvoidNon-dihydropyridine CCBs (diltiazem, verapamil) in EGFR-mutant patients, avoid; bevacizumab added to osimertinib for T790M+ progression (no benefit, increased toxicity); concurrent chemotherapy with reirradiation (adds toxicity without clear benefit); SBRT for ultra-central tumors outside clinical trials

DxTest of choicePET/CT for initial detection of suspected recurrence; tissue biopsy with repeat molecular profiling (EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS, PD-L1); tumor-informed ctDNA MRD testing for early relapse detection

ScKey scoreALBI grade (albumin-bilirubin), grade 1 best prognosis on anti-PD-1 therapy; grade 2 HR 1.60, grade 3 for OS

→When to referRadiation oncology for SBRT or reirradiation; neurosurgery for brain metastases; palliative care for symptom management; clinical trial for patients with progression on standard therapy

Recurrent NSCLC requires repeat molecular profiling to guide therapy; isolated locoregional recurrence may be curable with salvage surgery or reirradiation; distant disease is managed with biomarker-directed systemic therapy (osimertinib ± chemo or ramucirumab, sunvozertinib, poziotinib, pembrolizumab); oligometastatic disease (≤5 lesions) benefits from SBRT added to targeted therapy or immunotherapy; CNS-penetrant agents and double-dose osimertinib are key for brain metastases.

Recurrent or metastatic non-small cell lung cancer (NSCLC) carries a poor prognosis, but the emergence of targeted therapies and immune checkpoint inhibitors has transformed outcomes for patients with actionable drivers. The pattern of recurrence, local, regional, or distant, dictates the salvage strategy: isolated locoregional relapse may be curable with surgery or reirradiation, while distant disease requires systemic therapy guided by repeat molecular profiling. Oligometastatic disease (≤5 lesions) represents a distinct subset where metastasis-directed therapy with stereotactic body radiotherapy (SBRT) can prolong progression-free survival. This page provides a structured approach to evaluation and management, emphasizing biomarker-directed therapy, CNS-penetrant agents, and the integration of local therapies.

Overview and Recommendations

Background

•Recurrent NSCLC after initial curative-intent therapy (surgery, radiation, or chemoradiation) is classified by disease extent: local (same lobe), regional (ipsilateral hilum, mediastinum, or supraclavicular nodes), or distant (contralateral lung, pleura, liver, brain, bone). The pattern determines the salvage approach, isolated locoregional recurrence may be amenable to aggressive local therapy, while distant relapse almost always requires systemic treatment.
•The risk of recurrence is driven by tumor biology: intratumor copy-number heterogeneity (HR 4.9), visceral pleural invasion (5-year DFS 53.3% vs 65.9% without), and non-inflamed immune phenotype (KEAP1/STK11 co-mutations). ALK-positive NSCLC carries a high risk of brain relapse; adjuvant ensartinib 225 mg daily for 24 months reduced 24-month disease recurrence from 46.5% to 13.6% (HR 0.20).
•Molecular drivers evolve under selective pressure from prior therapy. Repeat biopsy (tissue or plasma ctDNA) is essential to identify resistance mechanisms (e.g., EGFR T790M after first-generation TKIs, bypass-track activation, or histologic transformation) and to detect new actionable alterations (EGFR, ALK, ROS1, BRAF V600E, METex14, RET, NTRK, KRAS G12C). PD-L1 expression may also change.
•Oligometastatic disease, defined as ≤5 lesions in ≤3 organs (NCCN) or ≤3 lesions (ESMO), represents a prognostically favorable subset. Metastasis-directed therapy with SBRT or resection can delay systemic therapy escalation and improve outcomes. The ABLATE trial in EGFR-mutant NSCLC showed that adding SBRT to lazertinib 240 mg daily extended median PFS to 34.0 months vs 24.8 months with lazertinib alone.
•Approximately 50% of patients with stage III NSCLC treated with chemoradiotherapy plus durvalumab will recur; of those, 72% have oligorecurrence (≤3 lesions). The most common sites are lung (34%) and brain (26%), and salvage local therapy significantly improves survival after recurrence (OS2).

Evaluation

•Suspect recurrence in any patient with treated NSCLC who develops new respiratory symptoms (cough, dyspnea, hemoptysis), constitutional symptoms (weight loss, fatigue), or neurologic deficits (headache, seizure, focal weakness). Routine surveillance imaging (CT chest with contrast) is performed every 3-6 months for the first 2-3 years, then annually.
•If CT findings are equivocal, or if there is clinical suspicion despite negative CT, order [18F]FDG PET/CT. PET/CT has significantly higher sensitivity (88% vs 62% for CT) for detecting recurrence, especially after chemoradiotherapy (100% vs 46%) and within the first 6 months after treatment (83% vs 41%). Specificity is lower (89% vs 96%) due to post-radiation inflammation.
•When imaging suggests recurrence, obtain histologic confirmation via image-guided core needle biopsy (CT or ultrasound) or endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for mediastinal/hilar lesions. A negative biopsy in a high-suspicion lesion should prompt repeat biopsy or multidisciplinary discussion.
•Perform repeat molecular profiling on the rebiopsy specimen: test for EGFR, ALK, ROS1, BRAF V600E, MET exon 14 skipping, RET, NTRK, KRAS G12C, and PD-L1 (22C3 or comparable assay). Resistance mutations (e.g., EGFR T790M) guide subsequent TKI selection. If tissue is insufficient, consider plasma ctDNA testing.
•Assess circulating tumor DNA (ctDNA) for molecular residual disease (MRD) and early relapse detection. Tumor-informed ctDNA assays (e.g., PROPHET) have a median lead time of 299 days to radiologic recurrence. In the LUNGCA-1 cohort, ctDNA positivity at postoperative day 3 or month 1 predicted relapse (HR 11.1), and MRD-positive patients who received adjuvant therapy had improved RFS (HR 0.3).
•Calculate the albumin-bilirubin (ALBI) grade as a simple prognostic tool. ALBI grade 2 vs 1 is associated with HR 1.60 for OS on anti-PD-1 therapy; grade 3 vs 1 with. This readily available lab value stratifies survival even in patients with ECOG PS 1-3 and can inform treatment decisions.
•For patients with isolated brain recurrence, obtain dedicated brain MRI with contrast. If leptomeningeal metastases are suspected, perform lumbar puncture for CSF cytology and ctDNA analysis.
•Evaluate performance status (ECOG PS), time to recurrence (postoperative recurrence has better prognosis than de novo stage IIIB/IV), and prior treatment history (platinum-free interval, prior TKI use, prior immunotherapy). These factors determine the intensity and choice of salvage therapy.

Management

•For isolated local recurrence after SABR or surgery, consider salvage surgery if R0 resection is feasible. Salvage pneumonectomy after high-dose CRT (≥60 Gy) yields median DFS of 14 months; 90-day mortality is 0% for pneumonectomy and 24% for lobectomy. Favorable outcomes are associated with recurrence >12 months after CRT and R0 resection.
•For local-regional recurrence not amenable to surgery, offer reirradiation with SBRT (preferred) or proton therapy. SBRT to a BED₁₀ ≥100 Gy achieves 2-year local failure of ~21.6% and median OS. Adhere to composite dose constraints: esophagus Dmax <120 Gy, lung V20 <40%, heart V40 <50%, spinal cord Dmax <57 Gy. Avoid concurrent chemotherapy with reirradiation if possible.
•For patients with EGFR-mutant metastatic recurrence and no prior third-generation TKI, start osimertinib 80 mg daily. Consider adding platinum-pemetrexed (4-6 cycles) if CNS metastases are present (FLAURA2: HR 0.58 for CNS progression). Alternatively, add ramucirumab 10 mg/kg IV every 3 weeks (RAMOSE: PFS 24.8 vs 15.6 months; NNT ≈7 at 12 months).
•For EGFR exon 20 insertion mutations in platinum-pretreated patients, use sunvozertinib 300 mg once daily (cORR 47.2%, median DOR 13.8 months). Monitor for grade ≥3 diarrhea (18%). For HER2 exon 20 insertions, poziotinib 16 mg once daily is an option (ORR 27.8%, median PFS 5.5 months) but carries high rates of rash (48.9%), diarrhea (25.6%), and stomatitis (24.4%) requiring dose reductions.
•For CNS-dominant recurrence in EGFR-mutant disease, escalate osimertinib to 160 mg daily (double dose). This achieves intracranial disease control rate of 92.5% and complete response rate of 12.5% in leptomeningeal metastases, with median OS 13.3 months. Alternatively, consider proton craniospinal irradiation (pCSI) which improved CNS PFS (7.5 vs 2.3 months) and OS (9.9 vs 6.0 months) compared to photon involved-field RT.
•For PD-L1-positive (≥1%) NSCLC with untreated brain metastases (5-20 mm, asymptomatic, no corticosteroids), treat with pembrolizumab 10 mg/kg every 2 weeks (brain metastasis response rate 29.7%). No responses are seen in PD-L1-negative patients.
•For oligometastatic disease (≤5 lesions) in treatment-naïve EGFR-mutant NSCLC, add SBRT to all metastatic sites (20 Gy in 1 fraction, 30 Gy in 3 fractions, or 35 Gy in 5 fractions) to lazertinib 240 mg once daily. The ABLATE trial showed median PFS of 34.0 months with no grade ≥3 radiation pneumonitis.
•For oligometastatic NSCLC without driver mutations, consider SBRT to all sites before or concurrent with immunotherapy. The PEMBRO-RT trial showed that SBRT (3 × 8 Gy) to a single tumor site before pembrolizumab improved ORR from 18% to 36%, especially in PD-L1-negative patients. The SKYROCKET trial reported median PFS of 9.3 months with SBRT + atezolizumab + tiragolumab.
•Do not use non-CNS penetrant first-generation EGFR TKIs (gefitinib, erlotinib) for patients with brain metastases if osimertinib is available. Avoid adding bevacizumab to osimertinib for T790M-positive patients after progression on first/second-generation TKIs (WJOG8715L showed no PFS benefit and increased toxicity). Avoid SBRT for ultra-central tumors outside clinical trials due to ~15% risk of grade 5 hemoptysis.
•Refer all patients with recurrent or metastatic NSCLC to a multidisciplinary tumor board for discussion of salvage local therapy, clinical trial enrollment, and palliative care integration. For patients with brain metastases, involve neurosurgery for consideration of surgical resection or stereotactic radiosurgery, and radiation oncology for whole-brain RT or pCSI if indicated.
•Monitor patients every 3 months with CT chest/abdomen/pelvis and brain MRI if CNS disease is present. Reassess molecular profile at progression. For patients on immunotherapy, monitor for immune-related adverse events (pneumonitis, colitis, hepatitis, endocrinopathies). Discontinue therapy if unacceptable toxicity or confirmed radiographic progression.

Board Review — High Yield

•Pattern of recurrence determiner, Isolated locoregional recurrence after SABR can be salvaged with surgery or reirradiation and yields 5-year OS similar to patients without recurrence (57.9% vs 54.9%). Distant recurrence requires systemic therapy.
•PET/CT superior to CT, Sensitivity 88% vs 62% for detecting recurrence, especially after chemoradiotherapy (100% vs 46%) and within 6 months (83% vs 41%). False positives from inflammation.
•ctDNA MRD, Tumor-informed ctDNA predicts relapse a median of 299 days before imaging; MRD-positive patients benefit from adjuvant therapy (HR 0.3).
•ALBI grade, Simple liver function index (albumin-bilirubin) that independently predicts OS on anti-PD-1 therapy: grade 2 HR 1.60, grade 3.
•FLAURA2, Adding platinum-pemetrexed to osimertinib reduces CNS progression in EGFR-mutant NSCLC (HR 0.58 for CNS progression; 24-month cumulative incidence 9% vs 23%).
•Ramose trial, Adding ramucirumab to osimertinib prolongs PFS (24.8 vs 15.6 months; HR 0.55); NNT ≈7 at 12 months.
•Sunvozertinib for EGFR exon20ins, 300 mg daily yields cORR 47.2%; effective in brain metastases (52.4% ORR in patients with baseline CNS lesions).
•Double-dose osimertinib (160 mg) for leptomeningeal metastases, Intracranial disease control rate 92.5%, median OS 13.3 months.
•ABLATE trial, SBRT to all sites (≤5 lesions) + lazertinib 240 mg daily in EGFR-mutant oligometastatic NSCLC: median PFS 34.0 vs 24.8 months; no grade ≥3 radiation pneumonitis.
•Ultra-central tumors contraindication, SBRT for ultra-central NSCLC carries ~15% risk of grade 5 hemoptysis; reserve for clinical trials.

Deep Dive — Evidence Details

Patterns of Recurrence

▸Recurrence pattern (local, regional, distant) drives the management algorithm for recurrent NSCLC.
▸GGO-dominant adenocarcinomas have a negligible risk of nodal and distant recurrence, supporting omission of mediastinal LND.
▸Brain metastases are a common and debilitating pattern; CNS-penetrant targeted therapy can delay intracranial progression.

HY High Yield: In patients with GGO-dominant lung adenocarcinoma (CTR ≤0.5, tumor ≤3 cm), systematic mediastinal lymph node dissection can be safely omitted because the risk of nodal metastasis is zero [7].

Recurrence pattern, local, regional, or distant, determines the subsequent management strategy for patients with previously treated NSCLC. The site and extent of relapse reflect the initial tumor biology, the adequacy of prior local therapy, and the effectiveness of systemic treatment. Understanding these patterns enables clinicians to select appropriate surveillance strategies and tailor salvage therapy.

Local and Regional Recurrence

Local recurrence refers to relapse at the primary tumor site after surgical resection or definitive radiotherapy. Regional recurrence involves the ipsilateral hilum, mediastinum, or supraclavicular lymph nodes. After , video-assisted thoracoscopic surgery ( ) and open lobectomy demonstrate comparable locoregional recurrence rates ^[2]^A1a. Systematic mediastinal lymph node dissection (LND) or sampling is standard for early-stage NSCLC, but in patients with ground-glass opacity (GGO)-dominant lung adenocarcinoma, the risk of mediastinal lymph node metastasis is negligible: a phase 3 trial (ECTOP-1009) found no lymph node metastases in 151 patients undergoing systematic LND, and no recurrence events occurred in either arm at interim analysis ^[7]^A1b. These data support selective LND for GGO-dominant tumors. For patients treated with ( ) for early-stage NSCLC, the incidence of regional recurrence is comparable to that after surgery, despite less invasive nodal staging, and occult nodal metastases increase the risk ^[10]^B2a.

Distant Recurrence

Distant (systemic) recurrence includes hematogenous spread to the contralateral lung, pleura, liver, adrenal glands, bone, and brain. The brain is a particularly common and debilitating site: from NSCLC are associated with shortened survival, impaired quality of life, and increased healthcare costs ^[11]^B2a. Prophylactic cranial irradiation (PCI) reduces the incidence of brain metastases in patients with non-metastatic NSCLC, but its impact on overall survival is less clear than in small-cell lung cancer ^[20]^A1b. The FLAURA2 study demonstrated that osimertinib plus platinum-pemetrexed chemotherapy delays CNS progression compared with osimertinib monotherapy in EGFR-mutated advanced NSCLC, with a CNS progression hazard ratio of 0.58 (95% CI 0.33 to 1.01) ^[6]^A1b. This underscores the importance of CNS-penetrant agents in preventing or delaying brain relapse.

Factors Influencing Recurrence Pattern

Several factors predict the pattern of recurrence:

Tumor biology and molecular drivers: Intratumor heterogeneity, particularly copy-number heterogeneity, is strongly associated with recurrence or death (HR 4.9, P=4.4×10⁻⁴) ^[14]^B2b. ALK-positive NSCLC has a high risk of distant and brain relapse; adjuvant ensartinib 225 mg once daily for 24 months improved 24-month disease-free survival from 53.5% to 86.4% (HR 0.20, 95% CI 0.11 to 0.38) ^[15]^A1b.
Surgical approach: VATS lobectomy may reduce systemic recurrence compared with open lobectomy ^[2]^A1a.
Adjuvant therapy: Adjuvant pazopanib in stage I NSCLC did not significantly improve recurrence-free survival (3-year RFS 76% vs 83%, HR 1.3, 95% CI 0.6-2.7) ^[8]^B2b.
Tumor histology: GGO-dominant adenocarcinomas have a very low risk of nodal and distant recurrence ^[7]^A1b.

The pattern of recurrence, locoregional versus distant, directly guides the choice between local consolidative therapy (e.g., re-resection, SBRT, or ) and systemic therapy. The next section details the recommended workup to confirm recurrence and characterize its extent.

Pearl: The recurrence pattern after initial therapy is the single most important determinant of salvage strategy: isolated locoregional relapse may be amenable to aggressive local therapy, while distant recurrence almost always requires systemic treatment, often with consideration of CNS-penetrant agents if brain metastases are present.

Workup of Suspected Recurrence

▸PET/CT has higher sensitivity than CT for detecting recurrence, especially after chemoradiotherapy (88% vs 62%) [28].
▸ctDNA-based MRD testing provides strong prognostic information (HR 11.1 for relapse) and can guide adjuvant therapy decisions [26].
▸The ALBI grade is an independent prognostic factor for survival in patients receiving immunotherapy, even after adjusting for performance status and PD-L1 expression [23].

Dx Diagnostic Essentials: ctDNA MRD testing can detect recurrence a median of 299 days before radiologic confirmation [39] and should be integrated into surveillance protocols for high-risk patients.

HY High Yield: The ALBI grade, calculated from serum albumin and bilirubin, is a cheap, objective prognostic marker for patients with recurrent NSCLC receiving immunotherapy, especially useful when PD-L1 status is unknown or performance status is poor [23].

Suspicion of recurrence, whether triggered by surveillance imaging, new symptoms, or rising tumor markers, requires a structured workup that integrates imaging, tissue confirmation, and molecular profiling. The pattern of recurrence (local, regional, distant, or a combination) dictates the urgency and choice of diagnostic modality.

Imaging for Suspected Recurrence

Computed tomography (CT) of the chest with intravenous contrast is the initial imaging test for routine surveillance, but its sensitivity is limited. In a secondary analysis of a randomized trial comparing CT and [18F]FDG PET/CT for recurrence detection, PET/CT demonstrated a significantly higher sensitivity (88%, 95% CI 80%-93%) versus CT (62%, 95% CI 50%-73%; P <.001), though with lower specificity (89% vs 96%, P <.001) ^[28]^A1b. The sensitivity advantage was most pronounced after chemoradiotherapy (100% vs 46%) and in the first 6 months after treatment (83% vs 41%; P =.008) ^[28]^A1b. The ACR Appropriateness Criteria endorse PET/CT as “usually appropriate” for evaluating suspected recurrence, particularly when CT findings are equivocal or when recurrence is suspected in a high-risk patient ^[22]^A1c.

Indications for PET/CT: rising tumor markers, equivocal CT findings, suspected extrathoracic metastases, or post-chemoradiotherapy surveillance.
Limitations: false-positive uptake from post-radiation inflammation or infection; lower specificity than CT.

Biopsy Confirmation

When imaging suggests recurrence, histologic confirmation is essential, especially if the lesion is solitary or if the patient is a candidate for local salvage therapy. Image-guided core needle biopsy (CT or ultrasound) or endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for mediastinal or hilar lesions provides tissue for both diagnosis and molecular testing. The false-negative rate of biopsy is low but non-zero; a negative biopsy in a high-suspicion lesion should prompt repeat biopsy or multidisciplinary discussion.

Molecular Profiling at Recurrence

Patients with recurrent or metastatic NSCLC should undergo repeat molecular testing on a rebiopsy specimen, as the NCCN guidelines recommend testing for actionable alterations including EGFR, ALK, ROS1, BRAF V600E, MET exon 14 skipping, RET, NTRK, and KRAS G12C ^[1]^A1c. PD-L1 immunohistochemistry should also be repeated, as expression may change after prior therapy. The emergence of a new resistance mutation (e.g., EGFR T790M after first-generation tyrosine kinase inhibitors) can guide selection of subsequent targeted therapy.

Circulating Tumor DNA and Minimal Residual Disease

Circulating tumor DNA (ctDNA) analysis has emerged as a powerful tool for detecting molecular residual disease (MRD) and predicting relapse. In the LUNGCA-1 prospective cohort, ctDNA positivity at postoperative day 3 or month 1 (MRD) was a strong predictor of disease relapse (HR = 11.1; P < 0.001), and MRD-positive patients who received adjuvant therapy had improved recurrence-free survival (HR = 0.3; P = 0.008) ^[26]^B2b. A meta-analysis of 30 studies (3,287 patients) confirmed that tumor-informed ctDNA assays achieve higher specificity (0.97) than tumor-agnostic approaches (0.93) in landmark analyses, while longitudinal monitoring narrows the gap (specificity 0.96 vs 0.88) ^[33]^B2a. The PROPHET personalized tumor-informed technology, using deep sequencing of 50 patient-specific variants, demonstrated a median lead time of 299 days to radiologically confirmed recurrence ^[39]^D5. Dynamic ctDNA monitoring also informs the response to adjuvant therapy: a negative-positive ctDNA pattern after adjuvant therapy is associated with worse recurrence-free survival (P < 0.001) ^[37]^B2b.

Test Strategy	Sensitivity (Landmark)	Specificity (Landmark)	AUC (Landmark)	Sensitivity (Longitudinal)	Specificity (Longitudinal)	AUC (Longitudinal)
Tumor-informed	0.42	0.97	0.81	0.76	0.96	0.86
Tumor-agnostic	0.44	0.93	0.70	0.79	0.88	0.91

Data from meta-analysis of 30 studies (N = 3,287) ^[33]^B2a.

Prognostic Biomarkers: The ALBI Grade

Beyond ctDNA, the albumin-bilirubin (ALBI) grade, a simple, objective index of liver function, is an independent prognostic factor for patients with advanced or recurrent NSCLC receiving anti-PD-1 therapy. In a multicenter retrospective study of 452 patients, ALBI grade 2 versus grade 1 was associated with a hazard ratio of 1.60 for overall survival (95% CI 1.24-2.07), and grade 3 versus grade 1 with HR 5.22 (95% CI 3.15-8.65) ^[23]^B3b. The ALBI grade remained significant after adjusting for , PD-L1 expression, and neutrophil-to-lymphocyte ratio, and it effectively stratified survival even in patients with poor performance status (PS 1-3) ^[23]^B3b. This readily available lab value can help refine prognosis and treatment decisions in patients being considered for immunotherapy.

Pearl: When a patient with treated NSCLC presents with a new lesion, obtain a PET/CT for highest sensitivity, and if the lesion is accessible, biopsy it for both histology and repeat molecular testing; ctDNA MRD testing can detect recurrence a median of 5-10 months before imaging, and a rising ALBI grade identifies patients with poor prognosis on immunotherapy.

Local-Regional Recurrence

▸Isolated locoregional recurrence after SABR for early-stage NSCLC occurs in ~10% of patients at 5 years; salvage treatment yields 5-year OS similar to patients without recurrence (57.9% vs 54.9%).
▸Salvage surgery after definitive CRT, immunotherapy, or targeted therapy is feasible with acceptable morbidity and can achieve long-term survival, especially when R0 resection and recurrence >12 months after initial treatment are achieved.
▸Reirradiation with SBRT or proton therapy provides durable local control (1-year local PFS 64-77%) but requires careful adherence to composite dose constraints to minimize grade ≥3 toxicity (reported in 6-42% of patients).

HY High Yield: Oligorecurrence (≤3 lesions) is the predominant pattern of relapse after CRT+durvalumab (72% of recurrences) and is associated with significantly better survival than polyrecurrence (median OS 41 vs 19 months) [41].

! Warning: SBRT reirradiation of centrally located lesions carries risk of severe toxicity, including fatal hemorrhage; use caution and consider proton therapy or hyperfractionation [40].

Management Guide for Treating Isolated Local Recurrence (iLR) and Isolated Regional Recurrence (iRR) After Stereotactic Ablative Radiotherapy (SABR) for Early-Stage Non–Small Cell Lung Cancer The workup involves positron emission tomography with computed tomography, magnetic resonance imaging of the brain, endobronchial ultrasound (if applicable based on findings of imaging), liver function tests, complete blood cell count, basic metabolic panel, and pulmonary function tests (if surgery is consi — Figure 1. — Management Guide for Treating Isolated Local Recurrence (iLR) and Isolated Regional Recurrence (iRR) After Stereotactic Ablative Radiotherapy (SABR) f...Europe PMC ↗

Once a suspected recurrence is confirmed, the pattern of failure, local, regional, or distant, dictates management. For patients with isolated locoregional recurrence, salvage treatment options include reirradiation, surgery, or thermal ablation, and can offer durable disease control and even cure in selected patients. The incidence and optimal approach depend on the initial treatment modality, the location of recurrence, and patient performance status.

Incidence and Patterns After Definitive Therapy

Local-regional recurrence after stereotactic ablative radiotherapy ( ) for early-stage NSCLC is infrequent. In a large retrospective analysis of 676 patients with PET-confirmed stage I-II NSCLC treated with SABR (54-60 Gy in 3-8 fractions), the actuarial 2-year rates of local and regional recurrence were 4.9% (95% CI 2.7-7.1) and 7.8% (95% CI 5.3-10.3), respectively; corresponding 5-year rates were 10.5% and 12.7% ^[24]^B3b. Isolated locoregional recurrence occurred in 34% of all recurrences, and 83% of these patients did not develop subsequent distant disease ^[24]^B3b.

After definitive chemoradiotherapy (CRT) for locally advanced NSCLC, the risk of locoregional failure is higher. In the PACIFIC regimen era, 56% of 166 patients with unresectable stage III NSCLC recurred after CRT plus consolidation; of these, 72% had oligorecurrence (≤3 lesions amenable to local therapy) ^[41]^B2b. The most common sites of oligorecurrence were lung (34%) and brain (26%), predominantly outside the irradiated field ^[41]^B2b. Among patients with driver mutations treated with definitive CRT, the pattern of failure did not differ significantly from those without mutations, but salvage local therapy for oligorecurrence significantly improved survival after recurrence (OS2) (P = 0.01) ^[48]^B3b.

Salvage Surgery

Salvage pulmonary resection for locoregional recurrence after definitive CRT or radiation is feasible in carefully selected patients and can yield long-term survival. In a multi-institutional series of 30 patients undergoing salvage surgery after high-dose CRT (≥60 Gy), was performed in 43% and in 57%. Median disease-free survival was 14 months after pneumonectomy and 6 months after lobectomy; 90-day mortality was 0% for pneumonectomy and 24% for lobectomy. Favorable outcomes were associated with R0 resection and recurrence >12 months after CRT ^[49]^B3b. Another institutional series of 15 patients reported a median overall survival of 46 months and event-free survival of 43.6 months after salvage surgery, with a 90-day mortality of 6.7% ^[56]^C4.

Salvage surgery after immunotherapy is also safe. A multi-institutional Japanese study of 32 patients who underwent salvage surgery after immune checkpoint inhibitors (ICIs) reported no perioperative mortality, a pathologic complete response in 18.8%, and 3-year OS of 86.9% from initial diagnosis. Conversion surgery (downstaging from initially unresectable) had superior 3-year recurrence-free survival compared with true salvage surgery for local recurrence (92.8% vs 36.3%; P = 0.010) ^[44]^C4.

For patients with ALK-rearranged NSCLC treated with first-line , salvage surgery appears feasible but technically challenging. In a multicenter series of 10 patients, alectinib (600 mg twice daily) was given for a mean of 212 days before surgery. R0 resection was achieved in all patients, and major pathological response (<10% viable tumor) was seen in 90%, including 50% pathologic complete response. Intraoperative difficulties related to perivascular fibrosis were common (70%), but major complications were absent ^[47]^C4.

Salvage surgery after carbon ion radiotherapy (CIRT) for early-stage NSCLC has also been reported. Among 12 patients who underwent salvage resection for local recurrence after CIRT (median 24 months post-CIRT), all surgeries were feasible without significant adhesions, no mortality or grade 3-4 complications occurred, and the 3-year survival after salvage was 82% ^[58]^B3b.

Salvage Reirradiation

Reirradiation for locoregional recurrence is a critical option when surgery is not feasible. The American Radium Society (ARS) Appropriate Use Criteria provide systematic guidance on thoracic reirradiation, recommending ( ) for primary-alone failures, ( ) over 3D-conformal, and caution with concurrent chemotherapy, which improves outcomes in nodal recurrences but adds toxicity ^[40]^A1c.

SBRT reirradiation achieves high local control. In a 72-patient series from the University of Pittsburgh, SBRT to a median BED₁₀ of 106 Gy yielded 2-year local failure of 21.6%, median PFS 15.2 months, and median OS 20.8 months, with 11.1% acute grade 3 toxicity and no grade ≥4 ^[40]^A1c. A 39-patient Memorial Sloan Kettering study reported 1- and 2-year local PFS of 77% and 64%, with median OS 22 months; BED₁₀ ≥100 Gy was associated with improved local PFS and OS ^[40]^A1c. In a series of 51 patients receiving 3 or more courses of definitive thoracic radiation (74% SBRT), median OS was 2.9 years, and the 3-year OS for patients who received SBRT for every course was 81%) ^[46]^C4. Notably, composite lung V20 >30% predicted grade ≥3 pneumonitis in SBRT reirradiation ^[40]^A1c.

may reduce toxicity. A prospective multi-institutional study of 57 patients treated with proton reirradiation (mean 66.6 Gy) reported 1-year OS of 59% and PFS of 58%. However, grade ≥3 acute or late toxicity occurred in 42%, and 6 grade 5 events were reported, underscoring the need for careful patient selection ^[55]^C4. Factors associated with high-grade toxicity include central airway overlap, mean esophagus dose, mean heart dose, and concurrent chemotherapy ^[55]^C4.

Dose constraints for reirradiation are summarized in Table 1. The ARS panel recommends composite plan EQD₂ constraints derived from the literature to minimize grade ≥3 toxicity ^[40]^A1c.

Organ at risk	Constraint (EQD₂)
Esophagus	V60 <40%, Dmax <100 Gy, avoid >110 Gy, strongly discourage >120 Gy
Lung	V20 <40%, V5 ≤65%, discourage V5 >75%
Heart	V40 <50%, mean heart dose as low as reasonably achievable
Aorta/great vessels	Dmax <120 Gy
Trachea/proximal bronchial tree	Dmax <110 Gy
Spinal cord	Dmax <57 Gy
Brachial plexus	Dmax <85 Gy

Table 1. Recommended composite dose constraints for thoracic reirradiation ^[40]^A1c.

Hyperfractionation may reduce late toxicities, but data are limited; no recommendations can be made for its routine use ^[40]^A1c.

Outcomes and Prognosis

Salvage treatment for isolated local recurrence (iLR) after SABR can yield survival similar to patients without recurrence. In a cohort of 912 patients with early-stage NSCLC treated with SABR, 5-year OS from initial SABR was 57.9% for iLR patients who received salvage treatment (reirradiation, surgery, thermal ablation, or chemotherapy) versus 54.9% for those without recurrence (HR 0.89, 95% CI 0.56-1.43) ^[43]^B2b. For isolated regional recurrence (iRR), salvage treatment resulted in 5-year OS of 31.1% (HR 1.43, 95% CI 1.00-2.34). Patients who received any salvage therapy lived longer than those who did not (median 37 vs 7 months from recurrence; HR 0.40, 95% CI 0.09-0.66) ^[43]^B2b. No grade 5 toxic effects occurred after salvage treatment ^[43]^B2b.

For patients with oligorecurrence after CRT and durvalumab, salvage radiotherapy (RT) alone or CRT provided median OS of 25 months and 30 months, respectively, versus 12 months for chemotherapy in polyrecurrent patients ^[41]^B2b. The median OS was significantly longer in oligorecurrent versus polyrecurrent patients (41 vs 19 months) ^[41]^B2b.

Pearl: Isolated locoregional recurrence after definitive therapy for NSCLC is potentially curable; salvage surgery or reirradiation with SBRT or proton therapy can achieve long-term survival in carefully selected patients, and multidisciplinary evaluation, including assessment of R0 resectability, BED ≥100 Gy for SBRT, and adherence to composite dose constraints, is essential.

Distant Metastatic Disease

▸Biomarker retesting at recurrence (biopsy or ctDNA) is mandatory to identify resistance mechanisms such as EGFR T790M, MET amplification, or histologic transformation.
▸For EGFR-mutant distant recurrence, osimertinib plus platinum-pemetrexed (FLAURA2) or ramucirumab (RAMOSE) improves PFS over osimertinib alone, with CNS benefit favoring the chemotherapy combination.
▸For CNS-dominant recurrence, double-dose osimertinib (160 mg) or proton craniospinal irradiation are effective salvage options in appropriately selected patients.

HY High Yield: In the FLAURA2 trial, mandatory baseline brain MRI detected CNS metastases in 40% of patients, nearly double the rate in FLAURA (23%) where scans were not mandated. Occult CNS disease is common; brain imaging is essential at recurrence [6].

When disease recurs at distant sites, treatment selection hinges on the same molecular drivers that guide initial therapy, but with two critical modifiers: the platinum-free interval and the mechanism of prior resistance. Biomarker retesting of a new biopsy or plasma ctDNA is essential because actionable alterations, including resistance mutations such as EGFR T790M, bypass-track activation, and histologic transformation, may emerge under selective pressure from prior therapy ^[77]^C4.

Biomarker-Directed Systemic Therapy

EGFR-mutant disease. For patients whose metastatic recurrence retains a sensitizing EGFR mutation and who have not received a third-generation TKI, osimertinib 80 mg daily remains the backbone. The FLAURA2 trial established that adding platinum-pemetrexed (4-6 cycles) to osimertinib improves progression-free survival (PFS) from 27.6 months to 30.2 months for CNS metastases, with a 42% reduction in the risk of CNS progression or death (HR 0.58; 95% CI 0.33-1.01; nominal) ^[6]^A1b. The RAMOSE trial showed that adding 10 mg/kg IV every 3 weeks to osimertinib prolongs PFS to 24.8 months versus 15.6 months (HR 0.55; 95% CI 0.32-0.93), with a 12-month PFS rate of 76.7% versus 61.9% (absolute difference; NNT to prevent one PFS event at 12 months ≈ 7) ^[64]^B2b. The AENEAS2 trial demonstrated that aumolertinib 110 mg daily plus platinum-pemetrexed yields a median PFS of 28.9 months versus 18.9 months with aumolertinib alone (HR 0.47; 95% CI 0.37-0.60; P<0.0001) ^[65]^A1b.

For patients who progress on a first- or second-generation EGFR TKI and acquire T790M, osimertinib 80 mg is standard. The WJOG8715L trial found that adding 15 mg/kg every 3 weeks did not improve PFS (9.4 months vs 13.5 months; adjusted HR 1.44; 80% CI 1.00-2.08) and increased grade ≥3 proteinuria (23%) and (20%) ^[71]^B2b.

EGFR exon 20 insertion mutations. For platinum-pretreated patients, sunvozertinib 300 mg once daily achieved a confirmed objective response rate (cORR) of 47.2% per IRC (97.5% CI 35.1-59.5; P<0.0001), with higher cORR in patients with baseline brain metastasis (52.4% vs 28.6% for 200 mg) and a median duration of response of 13.8 months ^[63]^B2b. Grade ≥3 diarrhea occurred in 18% at 300 mg.

HER2 exon 20 insertions. Poziotinib 16 mg once daily in previously treated patients (ZENITH20-2) yielded an objective response rate of 27.8% (95% CI 18.9-38.2), median PFS 5.5 months, and median duration of response 5.1 months. Grade ≥3 rash (48.9%), diarrhea (25.6%), and stomatitis (24.4%) were common, with 76.7% of patients requiring dose reductions ^[75]^B2b.

CNS Metastases: Intensified Approaches

CNS recurrence is particularly common in EGFR-mutant NSCLC. In the FLAURA2 analysis, among patients with baseline CNS metastases, the combination of osimertinib plus platinum-pemetrexed achieved a CNS complete response rate of 59% versus 43% with monotherapy, and the 24-month cumulative incidence of CNS progression was 9% versus 23% (absolute difference 14%; NNT to prevent one CNS progression at 24 months ≈ 7) ^[6]^A1b. For patients with , osimertinib 160 mg daily (double the standard dose) produced an intracranial disease control rate of 92.5% and a complete response rate of 12.5%, with median overall survival of 13.3 months ^[74]^B2b. Proton craniospinal irradiation (pCSI) improved CNS PFS compared with photon involved-field radiotherapy (median 7.5 months vs 2.3 months; P<0.001) and overall survival (9.9 months vs 6.0 months) in patients with leptomeningeal metastases from NSCLC and breast cancer, without increased grade 3-4 toxicity ^[62]^B2b.

Immunotherapy in CNS. In patients with PD-L1-positive (≥1%) NSCLC with untreated (5-20 mm, asymptomatic, no corticosteroids), 10 mg/kg every 2 weeks produced a brain metastasis response rate of 29.7% (95% CI 15.9-47.0) ^[67]^B2b. No responses were seen in PD-L1-negative patients.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Adding ramucirumab to osimertinib in first-line	NCCN Category 2A (RAMOSE data)	ESMO not yet formally included	Moderate	Shared decision-making based on toxicity profile and patient preference ^[64]^B2b
Osimertinib 160 mg for CNS progression after 80 mg	Supported by phase II data (Park 2020)	Not universally approved; some guidelines recommend local therapy first	Weak	Reasonable option for T790M+ patients with brain/leptomeningeal progression without alternative systemic options ^[74]^B2b

Pearl

For patients with EGFR-mutant NSCLC and distant metastatic recurrence, the decision to intensify therapy with chemotherapy or ramucirumab should be guided by the burden of CNS metastases, the platinum-free interval, and the patient's tolerance for added toxicity, the FLAURA2 and RAMOSE regimens both offer clinically meaningful PFS gains but with distinct adverse effect profiles.

Pearl: For CNS-dominant recurrence, double-dose osimertinib (160 mg) or proton craniospinal irradiation are effective salvage options in appropriately selected patients.

Selected First-Line Intensification Regimens for EGFR-Mutant Distant Metastatic NSCLC

Regimen	PFS (months)	HR (95% CI)	CNS benefit	Key toxicity
Osimertinib + platinum-pemetrexed (FLAURA2)	30.2 vs 27.6 (cFAS)	0.58 (0.33-1.01)	42% risk reduction; 59% CNS CR	64% grade ≥3 (cytopenias) ^[6]^A1b
Osimertinib + ramucirumab (RAMOSE)	24.8 vs 15.6	0.55 (0.32-0.93)	PFS benefit in CNS subgroup (17.9 vs 13.8 mo)	53% grade ≥3; hypertension 23% G3, epistaxis 41% G1-2 ^[64]^B2b
Aumolertinib + platinum-pemetrexed (AENEAS2)	28.9 vs 18.9	0.47 (0.37-0.60)	NR	Neutropenia 55% grade ≥3 ^[65]^A1b
Osimertinib 160 mg (BM/LM cohort)	7.6 (BM), 8.0 (LM)	N/A	CNS ORR 55% (BM), DCR 92.5% (LM)	Grade 1-2 diarrhea, rash ^[74]^B2b

Oligometastatic Disease

▸Oligometastatic NSCLC is variably defined (≤5 lesions per NCCN/IASLC, ≤3 per ESMO); the ABLATE trial used ≤5 lesions and demonstrated significant PFS benefit when adding SBRT to lazertinib.
▸SBRT combined with immunotherapy (pembrolizumab, atezolizumab/tiragolumab) shows response rates around 36% and median PFS of 9-10 months, with the greatest benefit in PD-L1-negative tumors.
▸SBRT for bone oligometastases achieves 2‑year local control >87% with low fracture rates; overall, SBRT preserves quality of life in most patients. Ultra‑central tumors require careful dose constraints to avoid grade 5 toxicity.

! Warning: Ultra‑central tumors (tumor overlapping proximal bronchus) carry a risk of grade 5 hemoptysis with SBRT; consider hypofractionated CRT or enrollment in clinical trials for these patients [80,92].

HY High Yield: In EGFR‑mutant oligometastatic NSCLC, the ABLATE trial demonstrated that adding upfront SBRT to lazertinib is safe and yields a median PFS of 34 months, longer than historical controls with TKI alone [81].

For patients with a limited number of metastatic sites, defined variably as ≤5 lesions in the NCCN and IASLC guidelines and ≤3 in the ESMO definition, metastasis-directed therapy with ( ) or surgical resection can prolong disease control and delay systemic therapy escalation. The ABLATE phase II trial defined synchronous oligometastatic disease as ≤5 metastatic lesions and enrolled treatment-naïve EGFR-mutant (ex19del or L858R) NSCLC patients ^[81]^B2b. Those receiving lazertinib 240 mg once daily plus SBRT to all sites (preferred doses: 20 Gy in 1 fraction, 30 Gy in 3 fractions, or 35 Gy in 5 fractions) achieved a median progression-free survival (PFS) of 34.0 months (90% CI 19.2 months-NR) versus 24.8 months (90% CI 15.7 months-NR) with lazertinib alone ^[81]^B2b. No grade ≥3 radiation pneumonitis was observed, and overall safety was manageable ^[81]^B2b.

SBRT in Combination with Immunotherapy

The PEMBRO-RT phase 2 trial randomized 76 patients with advanced NSCLC to alone or after SBRT (3 × 8 Gy) to a single tumor site. The overall response rate at 12 weeks was 18% in the control arm versus 36% in the SBRT-pembrolizumab arm, and the greatest benefit was seen in the PD-L1-negative subgroup ^[83]^B2b. The SKYROCKET phase 2 study reported a median PFS of 9.3 months (95% CI 6.0-NR) with SBRT to all metastatic sites followed by plus tiragolumab in PD-L1-positive NSCLC, without new safety signals ^[86]^B2b.

SBRT for Bone Oligometastases

In a European multicenter cohort of 85 patients with NSCLC and ≤5 bone oligometastases treated with SBRT, the 2-year freedom from local recurrence was 87.2% (95% CI 73.3%-), with fracture rates of only 5.4% and no grade 4-5 adverse events ^[94]^B2b.

Safety and Quality of Life across Oligometastatic Sites

The NRG-BR001 phase 1 trial established the safety of SBRT for patients with 3-4 metastases or 2 metastases in close proximity, with no dose-limiting toxicities and no treatment-related deaths ^[88]^C4. The LUSTRE trial, the largest SBRT RCT in stage I NSCLC, reported 3-year local control of 87.6% (95% CI 81.9%-) and low toxicity, though caution is warranted for ultra-central tumors where grade 5 hemoptysis occurred in 1 patient ^[80]^A1b. A meta-analysis of SBRT for ultra-central tumors found pooled 2-year local control of 84% (95% CI 77%-89%) and grade ≥3 toxicity of 9% (95% CI 6%-14%) ^[92]^B2a. The OligoCare prospective cohort (including NSCLC) showed that SBRT for oligometastases maintains overall health-related quality of life, with a stable median global health status score of 75 at baseline and 71 at follow-up ^[93]^B2b.

Controversies and Guideline Disagreement

The optimal number of oligometastatic lesions that qualifies for metastasis-directed therapy remains debated. The ESMO guideline defines oligometastasis as ≤3 lesions, while the NCCN guideline allows up to 5, and the IASLC definition permits ≤5 lesions in ≤3 organs ^[81]^B2b. The ABLATE trial used ≤5 lesions and demonstrated feasibility, but prospective validation is lacking. The use of SBRT for ultra-central tumors is also controversial: the LUSTRE trial reported a grade 5 hemoptysis event, and the HILUS trial noted 15% treatment-related death, prompting many guidelines to recommend SBRT only within clinical trials or with stringent dose constraints ^[80]^A1b^[92]^B2a.

Pearl: In treatment-naïve EGFR-mutant oligometastatic NSCLC (≤5 lesions), adding upfront SBRT to lazertinib yields a median PFS of 34 months with no grade ≥3 radiation pneumonitis ^[81]^B2b, a strategy that may obviate the need for combination chemotherapy or bispecific antibody therapy in selected patients.

Selected Trials of SBRT in Oligometastatic NSCLC

Study	Setting	Regimen	Key Efficacy Outcome	Safety
ABLATE (phase II) ^[81]^B2b	EGFR‑mutant, ≤5 lesions	Lazertinib 240 mg + SBRT vs lazertinib	Median PFS 34.0 vs 24.8 months	No grade ≥3 pneumonitis
SKYROCKET (phase II) ^[86]^B2b	PD‑L1+ advanced NSCLC	SBRT to all sites + atezolizumab + tiragolumab	Median PFS 9.3 months (95% CI 6.0‑NR)	No new safety signals
Bone SBRT cohort ^[94]^B2b	NSCLC, ≤5 bone metastases	SBRT to bone lesions	2‑yr FFLR 87.2%	5.4% fracture; no grade 4-5 AEs
NRG‑BR001 (phase I) ^[88]^C4	3-4 metastases or 2 in close proximity	SBRT per site‑specific schedule	No DLTs; median survival NR	No treatment‑related deaths

Prognosis of Recurrent Disease

▸Postoperative recurrence has a better prognosis than de novo stage IIIB/IV disease, with median survival exceeding 44 months in EGFR-mutant patients treated with gefitinib [98].
▸Visceral pleural invasion (VPI) upstages pT1 to pT2 and is associated with a 5-year DFS of 53.3% and a recurrence rate of 41.6%, independent of the extent of resection [108].
▸The ALBI grade and immune phenotype (inflamed vs non-inflamed) are independent prognostic factors in patients receiving anti-PD-1 therapy, with inflamed tumors showing a 39% reduction in hazard of death [96,23].

HY High Yield: In patients with recurrent NSCLC, the time to recurrence is a strong prognostic factor: postoperative recurrence carries a median survival approximately 17 months longer than de novo stage IIIB/IV disease in EGFR-mutant patients [98].

Oligometastatic disease represents a subset of recurrent NSCLC with a more favorable prognosis; however, for most patients, recurrence portends a poor outcome. The prognosis of recurrent NSCLC is determined by several clinical, molecular, and treatment-related factors, as summarized in the table below.

Prognostic Factors

Factor	Good Prognosis	Poor Prognosis
Disease extent at recurrence	Postoperative recurrence (median survival 44.5 months in gefitinib-treated EGFR-mutant patients) ^[98]^A1b	De novo stage IIIB/IV disease (median survival 27.5 months in gefitinib-treated EGFR-mutant patients) ^[98]^A1b
Visceral pleural invasion (VPI)	pT1 tumors (no VPI): 5-year DFS 65.9%, recurrence rate 27.6% ^[108]^A1b	pT2 tumors (VPI): 5-year DFS 53.3%, recurrence rate 41.6% ^[108]^A1b
Immune phenotype	Inflamed phenotype (CD8+ T-cell rich): HR 0.61 for disease-specific survival, HR 0.65 for time to recurrence ^[96]^B2b	Non-inflamed (altered/desert) phenotype; KEAP1/STK11 co-mutations enriched in non-inflamed LUAD ^[96]^B2b
Albumin-bilirubin (ALBI) grade	ALBI grade 1: significantly longer PFS and OS on anti-PD-1 therapy ^[23]^B3b	ALBI grade 2-3: shorter PFS and OS; ALBI grade is an independent prognostic factor ^[23]^B3b
Time to recurrence	Recurrence >3 years after surgery (associated with higher multigene testing rate) ^[107]^B3b	Recurrence ≤3 years after surgery ^[107]^B3b
Performance status	PS 0-1	ECOG PS ≥2 (associated with older age, less biomarker testing) ^[107]^B3b
Molecular drivers	EGFR mutation (exon 19 deletion or L858R) - median OS ~35-37 months with first-line TKI ^[98]^A1b; MET-positive tumors benefit from MET inhibition ^[103]^B2b	Absence of targetable driver; STK11/KEAP1 mutations ^[96]^B2b

Survival Outcomes by Pattern of Recurrence

After definitive treatment of early-stage NSCLC, the pattern of recurrence strongly influences prognosis. In a cohort of 676 patients treated with stereotactic ablative radiotherapy ( ) for stage I-II disease, the actuarial 5-year distant recurrence rate was 19.9%, while isolated locoregional recurrence occurred in 34% of those who recurred, and the majority of those patients (83%) did not develop subsequent distant disease ^[24]^B3b. The median time to distant recurrence was 9.6 months, compared with 14.9 months for local recurrence and 13.1 months for regional recurrence ^[24]^B3b. Salvage treatment for isolated locoregional recurrence is often feasible, underscoring the importance of surveillance.

Among patients with resected stage I NSCLC, the presence of visceral pleural invasion (VPI) upstages the tumor to pT2 and is associated with a significantly higher risk of recurrence. In the CALGB 140503 trial, the 5-year recurrence-free survival was 58.2% for pT2 tumors versus 73.1% for pT1 tumors, with distant recurrence as the predominant pattern (23.9% vs 14.6%) ^[108]^A1b. Importantly, recurrence rates were independent of the extent of resection (lobar vs sublobar), supporting the inclusion of these patients in adjuvant therapy trials ^[108]^A1b.

Impact of Perioperative Therapy and Molecular Testing

Postoperative recurrent NSCLC has a better prognosis than de novo advanced disease, even after adjusting for treatment. In the WJTOG3405 trial, median survival time was 44.5 months in patients with postoperative recurrence compared with 27.5 months in those with stage IIIB/IV disease, both receiving gefitinib ^[98]^A1b. A recent retrospective analysis of 229 patients with postoperative recurrence found that multigene testing was performed in only 43.7% of cases, despite the availability of surgical specimens, and that testing was less likely if recurrence occurred >3 years after surgery ^[107]^B3b. The adoption of broad molecular profiling is critical to identify actionable drivers and guide targeted therapy, which can improve outcomes in the recurrent setting.

Pearl: In patients with recurrent NSCLC, the best prognostic factor is the time to recurrence - postoperative recurrence carries a median survival approximately 17 months longer than de novo stage IIIB/IV disease in EGFR-mutant patients ^[98]^A1b. Visceral pleural invasion and a non-inflamed immune phenotype (especially with KEAP1/STK11 co-mutations) identify patients at highest risk and should prompt aggressive surveillance and consideration of adjuvant therapy ^[96]^B2b^[108]^A1b.

Key Prognostic Factors in Recurrent NSCLC

Factor	Good Prognosis	Poor Prognosis
Disease extent at recurrence	Postoperative recurrence (median survival 44.5 months in gefitinib-treated EGFR-mutant patients) ^[98]^A1b	De novo stage IIIB/IV disease (median survival 27.5 months in gefitinib-treated EGFR-mutant patients) ^[98]^A1b
Visceral pleural invasion (VPI)	pT1 tumors (no VPI): 5-year DFS 65.9%, recurrence rate 27.6% ^[108]^A1b	pT2 tumors (VPI): 5-year DFS 53.3%, recurrence rate 41.6% ^[108]^A1b
Immune phenotype	Inflamed phenotype (CD8+ T-cell rich): HR 0.61 for disease-specific survival, HR 0.65 for time to recurrence ^[96]^B2b	Non-inflamed (altered/desert) phenotype; KEAP1/STK11 co-mutations enriched in non-inflamed LUAD ^[96]^B2b
Albumin-bilirubin (ALBI) grade	ALBI grade 1: significantly longer PFS and OS on anti-PD-1 therapy ^[23]^B3b	ALBI grade 2-3: shorter PFS and OS; ALBI grade is an independent prognostic factor ^[23]^B3b
Time to recurrence	Recurrence >3 years after surgery (associated with higher multigene testing rate) ^[107]^B3b	Recurrence ≤3 years after surgery ^[107]^B3b
Performance status	ECOG PS 0-1	ECOG PS ≥2 (associated with older age, less biomarker testing) ^[107]^B3b
Molecular drivers	EGFR mutation (exon 19 deletion or L858R) - median OS ~35-37 months with first-line TKI ^[98]^A1b; MET-positive tumors benefit from MET inhibition ^[103]^B2b	Absence of targetable driver; STK11/KEAP1 mutations ^[96]^B2b

References

[1]
Ettinger DS, Wood DE, Aisner DL et al.. “Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35545176 ↗
L1GUIDELINECited in: Patterns of Recurrence, Workup of Suspected Recurrence
[2]
Yan TD, Black D, Bannon PG et al.. “Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19289625 ↗
L1SR_MA_RCTCited in: Patterns of Recurrence
[3]
Sugawara S, Lee JS, Kang JH et al.. “Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 34139272 ↗
L1RCTCited in: Patterns of Recurrence
[4]
Tanvetyanon T, Robinson LA, Schell MJ et al.. “Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18309950 ↗
L2SR_COHORTCited in: Patterns of Recurrence
[5]
Brahmer JR, Lee JS, Ciuleanu TE et al.. “Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36223558 ↗
L1RCTCited in: Patterns of Recurrence
[6]
Jänne PA, Planchard D, Kobayashi K et al.. “CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 38042525 ↗
L1RCTCited in: Patterns of Recurrence, Distant Metastatic Disease
[7]
Zhang Y, Qian B, Song Q et al.. “Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity-Dominant Lung Adenocarcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40690727 ↗
L1RCTCited in: Patterns of Recurrence
[8]
Besse B, Mazières J, Ribassin-Majed L et al.. “Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28327934 ↗
L2RCT_PHASE2Cited in: Patterns of Recurrence, Prognosis of Recurrent Disease
[9]
Allignet B, De Ruysscher D, Martel-Lafay I et al.. “Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: A systematic review.” Cancer treatment reviews (2023). PMID: 37210766 ↗
L4SR_COHORTCited in: Patterns of Recurrence, Oligometastatic Disease
[10]
Wink KCJ, van Baardwijk A, Troost EGC et al.. “Nodal recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: Incidence and proposed risk factors.” Cancer treatment reviews (2017). PMID: 28437679 ↗
L2SR_COHORTCited in: Patterns of Recurrence, Oligometastatic Disease
[11]
Peters S, Bexelius C, Munk V et al.. “The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer.” Cancer treatment reviews (2016). PMID: 27019457 ↗
L2SR_COHORTCited in: Patterns of Recurrence
[12]
Yoshimura A, Takeda T, Tanimura K et al.. “Impact of the Lung Immune Prognostic Index in non-small-cell lung cancer patients with PD-L1-low/negative tumors receiving chemoimmunotherapy: a real-world multicenter retrospective study.” ESMO open (2025). PMID: 41270701 ↗
L2PROSPECTIVE_COHORTCited in: Patterns of Recurrence
[13]
Ito K, Morise M, Wakuda K et al.. “A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903.” ESMO open (2021). PMID: 33984681 ↗
L2PROSPECTIVE_COHORTCited in: Patterns of Recurrence
[14]
Jamal-Hanjani M, Wilson GA, McGranahan N et al.. “Tracking the Evolution of Non-Small-Cell Lung Cancer.” The New England journal of medicine (2017). PMID: 28445112 ↗
L2PROSPECTIVE_COHORTCited in: Patterns of Recurrence
[15]
Yue D, Huang M, Song P et al.. “Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.” The New England journal of medicine (2026). PMID: 42418775 ↗
L1RCTCited in: Patterns of Recurrence
[16]
Borghaei H, O'Byrne KJ, Paz-Ares L et al.. “Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.” ESMO open (2023). PMID: 37988950 ↗
L1RCTCited in: Patterns of Recurrence
[17]
O'Byrne KJ, Lee KH, Kim SW et al.. “First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients.” ESMO open (2022). PMID: 35158207 ↗
L1RCTCited in: Patterns of Recurrence
[18]
Reck M, Ciuleanu TE, Cobo M et al.. “First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.” ESMO open (2021). PMID: 34607285 ↗
L1RCTCited in: Patterns of Recurrence
[19]
Paz-Ares L, Ciuleanu TE, Cobo M et al.. “First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.” The Lancet. Oncology (2021). PMID: 33476593 ↗
L1RCTCited in: Patterns of Recurrence, Prognosis of Recurrent Disease
[20]
Péchoux CL, Sun A, Slotman BJ et al.. “Prophylactic cranial irradiation for patients with lung cancer.” The Lancet. Oncology (2016). PMID: 27396646 ↗
L1RCTCited in: Patterns of Recurrence
[21]
Chun SG, Hu C, Choy H et al.. “Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 28034064 ↗
L1RCTCited in: Workup of Suspected Recurrence, Prognosis of Recurrent Disease
[22]
Madan R, El Alam RH, Walker CM et al.. “ACR Appropriateness Criteria® Lung Cancer-Surveillance After Therapy.” Journal of the American College of Radiology : JACR (2025). PMID: 40409885 ↗
L1GUIDELINECited in: Workup of Suspected Recurrence
[23]
Takada K, Takamori S, Shimokawa M et al.. “Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy.” ESMO open (2021). PMID: 34942439 ↗
L3COHORTCited in: Workup of Suspected Recurrence, Prognosis of Recurrent Disease
[24]
Senthi S, Lagerwaard FJ, Haasbeek CJ et al.. “Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.” The Lancet. Oncology (2012). PMID: 22727222 ↗
L3RETROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence, Local-Regional Recurrence, Prognosis of Recurrent Disease
[25]
Loganadane G, Martinetti F, Mercier O et al.. “Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: A critical literature review of predictive factors of relapse.” Cancer treatment reviews (2016). PMID: 27768919 ↗
L5NARRATIVE_REVIEWCited in: Workup of Suspected Recurrence
[26]
Xia L, Mei J, Kang R et al.. “Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 34844976 ↗
L2PROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence
[27]
Sandhu SK, Schelman WR, Wilding G et al.. “The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.” The Lancet. Oncology (2013). PMID: 23810788 ↗
L4PHASE_1_TRIALCited in: Workup of Suspected Recurrence
[28]
Guldbrandsen KF, Bloch M, Skougaard K et al.. “Diagnostic Accuracy of [18F]FDG PET/CT versus CT for NSCLC Surveillance: Secondary Analysis of a Randomized Clinical Trial.” Clinical lung cancer (2025). PMID: 41387040 ↗
L1RCTCited in: Workup of Suspected Recurrence
[29]
Zhang JT, Liu SY, Gao X et al.. “Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39853318 ↗
L4COHORTCited in: Workup of Suspected Recurrence
[30]
Arcidiacono F, Anselmo P, Casale M et al.. “Five-Year Survival and Safety of SABR in Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer unfit for Concurrent Radio-chemotherapy: Focus on Patterns of Local Recurrence from the START-NEW-ERA Non-randomized Phase 2 Trial.” International journal of radiation oncology, biology, physics (2025). PMID: 40992670 ↗
L2RCT_PHASE2Cited in: Workup of Suspected Recurrence
[31]
Wu J, Zhang Y, Wang J et al.. “Accuracy of Radiomics-Based Machine Learning for Predicting Risk of Recurrence in Non-Small Cell Lung Cancer: Systematic Review and Meta-Analysis.” Journal of medical Internet research (2026). PMID: 41940422 ↗
L2SR_COHORTCited in: Workup of Suspected Recurrence
[32]
Yang Y, He H, Yu C et al.. “Artificial Intelligence Models to Predict Recurrence Risk Prediction in Early-Stage Non-Small Cell Lung Cancer: A Systematic Review.” European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2026). PMID: 41666303 ↗
L2SR_COHORTCited in: Workup of Suspected Recurrence
[33]
Lu D, Lin N, Li S et al.. “Predictive Effectiveness of Circulating Tumor DNA in Recurrent Early-Stage Non-Small Cell Lung Cancer: An Updated Meta-Analysis.” JCO precision oncology (2025). PMID: 41066727 ↗
L2SR_COHORTCited in: Workup of Suspected Recurrence
[34]
Lanuti M, Suh RD, Criner GJ et al.. “Systematic Review of Image-Guided Thermal Ablation for Treatment of High-Risk Patients with Stage I Non-Small Cell Lung Cancer.” Seminars in thoracic and cardiovascular surgery (2024). PMID: 39662536 ↗
L2SR_COHORTCited in: Workup of Suspected Recurrence
[35]
Hou J, Xiao J, Yang B et al.. “Value of RASSF1A and SHOX2 methylation detection in intraoperative pleural lavage fluid for potential microdissemination and prognosis evaluation in non-small cell lung cancer.” World journal of surgical oncology (2026). PMID: 42116130 ↗
L2PROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence
[36]
Toth AJ, Robert SM, Fahy T et al.. “Multidisciplinary review outperforms qualitative MR perfusion in distinguishing post-radiation brain metastasis recurrence versus radionecrosis.” Journal of neuro-oncology (2025). PMID: 41219616 ↗
L2PROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence
[37]
Xia L, Pu Q, Kang R et al.. “Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study).” Journal of the National Cancer Institute (2025). PMID: 40131728 ↗
L2PROSPECTIVE_COHORTCited in: Workup of Suspected Recurrence
[38]
. “MRD May Predict Relapse in NSCLC.” Cancer discovery (2020). PMID: 32467342 ↗
L5OTHERCited in: Workup of Suspected Recurrence
[39]
Chen K, Yang F, Shen H et al.. “Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer.” Cancer cell (2023). PMID: 37683638 ↗
L5OTHERCited in: Workup of Suspected Recurrence
[40]
Simone CB, Amini A, Chetty IJ et al.. “American Radium Society Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-Small Cell Lung Cancer Executive Summary.” International journal of radiation oncology, biology, physics (2025). PMID: 40185207 ↗
L1GUIDELINECited in: Local-Regional Recurrence
[41]
Ciammella P, Iori F, Borghetti P et al.. “Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial).” Lung cancer (Amsterdam, Netherlands) (2025). PMID: 40876065 ↗
L2PROSPECTIVE_COHORTCited in: Local-Regional Recurrence
[42]
Munoz-Schuffenegger P, Kandel S, Alibhai Z et al.. “A Prospective Study of Magnetic Resonance Imaging Assessment of Post-radiation Changes Following Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer.” Clinical oncology (Royal College of Radiologists (Great Britain)) (2019). PMID: 31176537 ↗
L4PROSPECTIVE_COHORTCited in: Local-Regional Recurrence
[43]
Brooks ED, Sun B, Feng L et al.. “Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.” JAMA network open (2018). PMID: 30646121 ↗
L2PROSPECTIVE_COHORTCited in: Local-Regional Recurrence
[44]
Tane S, Nishikubo M, Manabe T et al.. “Efficacy and Safety of Salvage Surgery After Immunotherapy in Non-small Cell Lung Cancer: A Multi-institutional Retrospective Study.” Annals of surgical oncology (2026). PMID: 41746575 ↗
L4COHORTCited in: Local-Regional Recurrence
[45]
Vuppala NK, LeCompte MC, Patel PP et al.. “Oncological outcomes and safety after spinal reirradiation with stereotactic body radiotherapy.” Journal of neurosurgery. Spine (2025). PMID: 40939207 ↗
L3COHORTCited in: Local-Regional Recurrence
[46]
Odwuor A, Lee P, Chang JY et al.. “Outcomes and Toxicity following 3 or More Definitive Courses of Thoracic Radiation Therapy for Non-Small Cell Lung Cancer.” Clinical lung cancer (2025). PMID: 40318943 ↗
L4COHORTCited in: Local-Regional Recurrence
[47]
Lococo F, Cancellieri A, Chiappetta M et al.. “Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results.” Clinical lung cancer (2023). PMID: 37061413 ↗
L4COHORTCited in: Local-Regional Recurrence
[48]
Zhang J, Mao J, Xu D et al.. “Pattern of failure and clinical value of local therapy for oligo-recurrence in locally advanced non-small cell lung cancer after definitive chemoradiation: Impact of driver mutation status.” Cancer medicine (2022). PMID: 36524618 ↗
L3COHORTCited in: Local-Regional Recurrence
[49]
Joosten PJM, Dickhoff C, van der Noort V et al.. “Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?” Lung cancer (Amsterdam, Netherlands) (2020). PMID: 33220611 ↗
L3COHORTCited in: Local-Regional Recurrence
[50]
Muller DA, Dutta SW, Aliotta E et al.. “Clinical Outcomes and Predictors of Lung Toxicity After Multiple Courses of Lung Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.” Clinical lung cancer (2020). PMID: 32690439 ↗
L4COHORTCited in: Local-Regional Recurrence
[51]
Kowalchuk RO, Waters MR, Richardson KM et al.. “Stereotactic Body Radiation Therapy for Salvage Treatment of Recurrent Non-Small Cell Lung Cancer.” Practical radiation oncology (2020). PMID: 32454175 ↗
L4COHORTCited in: Local-Regional Recurrence
[52]
Kobayashi AK, Horinouchi H, Nakayama Y et al.. “Salvage surgery after chemotherapy and/or radiotherapy including SBRT and proton therapy: A consecutive analysis of 38 patients.” Lung cancer (Amsterdam, Netherlands) (2020). PMID: 32422344 ↗
L4COHORTCited in: Local-Regional Recurrence
[53]
Saleh K, Daste A, Martin N et al.. “Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.” European journal of cancer (Oxford, England : 1990) (2019). PMID: 31574417 ↗
L4COHORTCited in: Local-Regional Recurrence
[54]
Grass GD, Naghavi AO, Abuodeh YA et al.. “Analysis of Relapse Events After Definitive Chemoradiotherapy in Locally Advanced Non-Small-Cell Lung Cancer Patients.” Clinical lung cancer (2018). PMID: 30268836 ↗
L3COHORTCited in: Local-Regional Recurrence
[55]
Chao HH, Berman AT, Simone CB et al.. “Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer.” Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2016). PMID: 27826034 ↗
L4COHORTCited in: Local-Regional Recurrence
[56]
Dickhoff C, Dahele M, Paul MA et al.. “Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer.” Lung cancer (Amsterdam, Netherlands) (2016). PMID: 26973215 ↗
L4COHORTCited in: Local-Regional Recurrence
[57]
Binkley MS, Hiniker SM, Chaudhuri A et al.. “Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation.” International journal of radiation oncology, biology, physics (2015). PMID: 26831903 ↗
L4COHORTCited in: Local-Regional Recurrence
[58]
Mizobuchi T, Yamamoto N, Nakajima M et al.. “Salvage surgery for local recurrence after carbon ion radiotherapy for patients with lung cancer.” European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2015). PMID: 26468271 ↗
L3COHORTCited in: Local-Regional Recurrence
[59]
Liao Z, Lee JJ, Komaki R et al.. “Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29293386 ↗
L1RCTCited in: Distant Metastatic Disease
[60]
Scagliotti GV, Krzakowski M, Szczesna A et al.. “Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22564989 ↗
L1RCTCited in: Distant Metastatic Disease
[61]
Kurup A, Lin C-, Murry DJ et al.. “Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University.” Annals of oncology : official journal of the European Society for Medical Oncology (2005). PMID: 16282244 ↗
L2RCT_PHASE2Cited in: Distant Metastatic Disease
[62]
Yang JT, Wijetunga NA, Pentsova E et al.. “Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35802849 ↗
L2RCT_PHASE2Cited in: Distant Metastatic Disease
[63]
Yang JC, Wang M, Doucet L et al.. “Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40923280 ↗
L2RCT_PHASE2Cited in: Distant Metastatic Disease
[64]
Le X, Patel JD, Shum E et al.. “A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39378386 ↗
L2RCT_PHASE2Cited in: Distant Metastatic Disease
[65]
Li Z, Hu J, Chen J et al.. “Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.” The Lancet. Oncology (2026). PMID: 42296979 ↗
L1RCTCited in: Distant Metastatic Disease
[66]
Antonia SJ, Villegas A, Daniel D et al.. “Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.” The New England journal of medicine (2018). PMID: 30280658 ↗
L1RCTCited in: Distant Metastatic Disease
[67]
Goldberg SB, Schalper KA, Gettinger SN et al.. “Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.” The Lancet. Oncology (2020). PMID: 32251621 ↗
L2RCT_PHASE2Cited in: Distant Metastatic Disease
[68]
Goldberg SB, Gettinger SN, Mahajan A et al.. “Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.” The Lancet. Oncology (2016). PMID: 27267608 ↗
L2RCT_PHASE2Cited in: Distant Metastatic Disease
[69]
Hui Z, Men Y, Hu C et al.. “Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.” JAMA oncology (2021). PMID: 34165501 ↗
L1RCTCited in: Distant Metastatic Disease
[70]
Wang HM, Liao ZX, Komaki R et al.. “Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23300016 ↗
L2PROSPECTIVE_COHORTCited in: Distant Metastatic Disease
[71]
Akamatsu H, Toi Y, Hayashi H et al.. “Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.” JAMA oncology (2021). PMID: 33410885 ↗
L2RCT_PHASE2Cited in: Distant Metastatic Disease
[72]
Provencio M, Serna-Blasco R, Nadal E et al.. “Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41537692 ↗
L1RCTCited in: Distant Metastatic Disease
[73]
Santini D, Galluzzo S, Vincenzi B et al.. “New developments of aminobisphosphonates: the double face of Janus.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17591815 ↗
L2NON_RANDOMIZED_TRIALCited in: Distant Metastatic Disease
[74]
Park S, Lee MH, Seong M et al.. “A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 32634610 ↗
L2NON_RANDOMIZED_TRIALCited in: Distant Metastatic Disease
[75]
Le X, Cornelissen R, Garassino M et al.. “Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34843401 ↗
L2NON_RANDOMIZED_TRIALCited in: Distant Metastatic Disease
[76]
Welsh JW, Komaki R, Amini A et al.. “Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23341526 ↗
L2NON_RANDOMIZED_TRIALCited in: Distant Metastatic Disease
[77]
Chen L, Davelaar J, Gaddam S et al.. “Early Application of Next-Generation Sequencing Identifies Pancreatic Mass as Metastasis From an EGFR-Mutated Lung Adenocarcinoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 36395704 ↗
L4CASE_SERIESCited in: Distant Metastatic Disease
[78]
Altorki NK, McGraw TE, Borczuk AC et al.. “Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.” The Lancet. Oncology (2021). PMID: 34015311 ↗
L2RCT_PHASE2Cited in: Oligometastatic Disease
[79]
Baumann P, Nyman J, Hoyer M et al.. “Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19414667 ↗
L2NON_RANDOMIZED_TRIALCited in: Oligometastatic Disease
[80]
Swaminath A, Parpia S, Wierzbicki M et al.. “Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial.” JAMA oncology (2024). PMID: 39298144 ↗
L1RCTCited in: Oligometastatic Disease
[81]
Lee JB, Kim KH, Yoon S et al.. “Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer.” ESMO open (2026). PMID: 41604814 ↗
L2NON_RANDOMIZED_TRIALCited in: Oligometastatic Disease
[82]
Heinzerling JH, Mileham KF, Robinson MM et al.. “Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.” The Lancet. Oncology (2024). PMID: 39615497 ↗
L2NON_RANDOMIZED_TRIALCited in: Oligometastatic Disease
[83]
Theelen WSME, Peulen HMU, Lalezari F et al.. “Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.” JAMA oncology (2019). PMID: 31294749 ↗
L2RCT_PHASE2Cited in: Oligometastatic Disease
[84]
Bezjak A, Paulus R, Gaspar LE et al.. “Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 30943123 ↗
L4PHASE_1_TRIALCited in: Oligometastatic Disease
[85]
Simpson DR, Sanghvi P, Sandhu AP. “Lung stereotactic body radiotherapy for early-stage NSCLC in patients with prior pneumonectomy: a case report.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 25361797 ↗
L4CASE_SERIESCited in: Oligometastatic Disease
[86]
Lee JB, Kim DK, Lee SH et al.. “A Phase II Study of Stereotactic Ablative Radiotherapy plus Atezolizumab plus Tiragolumab in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 42008740 ↗
L2NON_RANDOMIZED_TRIALCited in: Oligometastatic Disease
[87]
Wang Y, Donovan EK, Levine MN et al.. “Stereotactic Versus Conventional Radiotherapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer: A Bayesian Reanalysis of the LUSTRE Randomized Trial.” Clinical lung cancer (2026). PMID: 41997828 ↗
L1RCTCited in: Oligometastatic Disease
[88]
Chmura S, Winter KA, Robinson C et al.. “Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial.” JAMA oncology (2021). PMID: 33885704 ↗
L4PHASE_1_TRIALCited in: Oligometastatic Disease
[89]
Asami M, Katsumata S, Yasui K et al.. “Comparison of treatment outcomes between stereotactic body radiotherapy/proton beam therapy and sublobar resection for vulnerable elderly patients with stage IA non-small cell lung cancer.” Japanese journal of clinical oncology (2026). PMID: 41215492 ↗
L1RCTCited in: Oligometastatic Disease
[90]
Zhou X, Zhou L, Yao Z et al.. “Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37581611 ↗
L4PHASE_1_TRIALCited in: Oligometastatic Disease
[91]
Adar S, Ádám A, Balogh T et al.. “Sublobar resection, stereotactic body radiotherapy, and thermal ablation for early-stage non-small cell lung cancer: a systematic review and meta-analysis.” Lung cancer (Amsterdam, Netherlands) (2026). PMID: 42202379 ↗
L2SR_COHORTCited in: Oligometastatic Disease
[92]
Zeng H, Wang X, Bai H et al.. “Stereotactic body radiation therapy for ultra-central lung malignancies: an updated systematic review and meta-analysis.” Radiation oncology (London, England) (2026). PMID: 42116164 ↗
L2SR_COHORTCited in: Oligometastatic Disease
[93]
Greto D, Van Hemelrijck M, Oppong F et al.. “Short-term quality of life after metastases-directed SBRT: Results of the ESTRO & EORTC OligoCare cohort.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2026). PMID: 42314835 ↗
L2PROSPECTIVE_COHORTCited in: Oligometastatic Disease
[94]
Schäfer S, Seiler I, Balermpas P et al.. “Outcome of patients with lung cancer treated with stereotactic body radiotherapy for bone oligometastases - a European multicenter cohort study.” Radiation oncology (London, England) (2026). PMID: 42157246 ↗
L2PROSPECTIVE_COHORTCited in: Oligometastatic Disease
[95]
Zygogianni A, Kougioumtzopoulou A, Platoni K et al.. “Real-World Data on the Safety and Efficacy of SBRT for Central and Ultra-Central Lung Tumors: A Retrospective Multi-Center Cohort.” Cancers (2026). PMID: 41749905 ↗
L4PROSPECTIVE_COHORTCited in: Oligometastatic Disease
[96]
Rakaee M, Andersen S, Giannikou K et al.. “Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37100205 ↗
L2PROSPECTIVE_COHORTCited in: Prognosis of Recurrent Disease
[97]
Kelly RJ, Shepherd FA, Krivoshik A et al.. “A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31070709 ↗
L1RCTCited in: Prognosis of Recurrent Disease
[98]
Yoshioka H, Shimokawa M, Seto T et al.. “Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31553438 ↗
L1RCTCited in: Prognosis of Recurrent Disease
[99]
Reck M, von Pawel J, Zatloukal P et al.. “Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20150572 ↗
L1RCTCited in: Prognosis of Recurrent Disease
[100]
Landreneau RJ, Normolle DP, Christie NA et al.. “Recurrence and survival outcomes after anatomic segmentectomy versus lobectomy for clinical stage I non-small-cell lung cancer: a propensity-matched analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 24982447 ↗
L2PROSPECTIVE_COHORTCited in: Prognosis of Recurrent Disease
[101]
Zhou C, Wu YL, Chen G et al.. “BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26014294 ↗
L1RCTCited in: Prognosis of Recurrent Disease
[102]
Vansteenkiste JF, Cho BC, Vanakesa T et al.. “Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet. Oncology (2016). PMID: 27132212 ↗
L1RCTCited in: Prognosis of Recurrent Disease
[103]
Spigel DR, Ervin TJ, Ramlau RA et al.. “Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24101053 ↗
L2RCT_PHASE2Cited in: Prognosis of Recurrent Disease
[104]
Kubota K, Yoshioka H, Oshita F et al.. “Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28902534 ↗
L2RCT_PHASE2Cited in: Prognosis of Recurrent Disease
[105]
Schild SE, Vokes EE. “Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26712904 ↗
L2NON_RANDOMIZED_TRIALCited in: Prognosis of Recurrent Disease
[106]
Siena S, Crinò L, Danova M et al.. “Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19767314 ↗
L2NON_RANDOMIZED_TRIALCited in: Prognosis of Recurrent Disease
[107]
Matsubara T, Sakamoto T, Takahama T et al.. “Gene testing and prognosis in post-operative recurrent non-small-cell lung cancer: subgroup analyses of WJOG15421L.” ESMO open (2026). PMID: 41922144 ↗
L3RETROSPECTIVE_COHORTCited in: Prognosis of Recurrent Disease
[108]
Altorki N, Wang X, Damman B et al.. “Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Secondary Analysis of a Randomized Clinical Trial.” JAMA oncology (2024). PMID: 39088196 ↗
L1RCTCited in: Prognosis of Recurrent Disease
[109]
Chang JY, Senan S, Paul MA et al.. “Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.” The Lancet. Oncology (2015). PMID: 25981812 ↗
L2RCT_PHASE2Cited in: Prognosis of Recurrent Disease
[110]
Kim ES, Neubauer M, Cohn A et al.. “Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.” The Lancet. Oncology (2013). PMID: 24231627 ↗
L2RCT_PHASE2Cited in: Prognosis of Recurrent Disease

Non-Small Cell Lung Cancer Recurrent and Metastatic Disease

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Patterns of Recurrence

Local and Regional Recurrence

Distant Recurrence

Factors Influencing Recurrence Pattern

Workup of Suspected Recurrence

Imaging for Suspected Recurrence

Biopsy Confirmation

Molecular Profiling at Recurrence

Circulating Tumor DNA and Minimal Residual Disease

Prognostic Biomarkers: The ALBI Grade

Local-Regional Recurrence

Incidence and Patterns After Definitive Therapy

Salvage Surgery

Salvage Reirradiation

Outcomes and Prognosis

Distant Metastatic Disease

Biomarker-Directed Systemic Therapy

CNS Metastases: Intensified Approaches

Controversies and Guideline Disagreement

Pearl

Oligometastatic Disease

SBRT in Combination with Immunotherapy

SBRT for Bone Oligometastases

Safety and Quality of Life across Oligometastatic Sites

Controversies and Guideline Disagreement

Prognosis of Recurrent Disease

Prognostic Factors

Survival Outcomes by Pattern of Recurrence

Impact of Perioperative Therapy and Molecular Testing

Related Pages

References

Revision History